LEXINGTON, Mass. — August 12, 2025 — Leads & Copy — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) reported its financial results for the second quarter ended June 30, 2025, showcasing a 10% increase in total revenue, reaching $7.3 million compared to Q2 2024. Recurring revenue saw a 15% rise during the same period. Gross margin improved to 4%, up from -3% in the previous year’s quarter.
The company also entered a five-year, $45 million term loan facility, with $20 million already funded. Rapid Micro Biosystems reaffirmed its full-year 2025 total revenue guidance of at least $32.0 million.
President and CEO Robert Spignesi noted the quarter’s broad-based execution and highlighted an 18% increase in Service revenue and a 6% rise in Product revenue, driven by consumables growth. The new loan facility is expected to strengthen the company’s financial position and support its focus on long-term revenue growth and shareholder value.
The company’s strategic priorities remain unchanged, and this capital supports our continued focus on delivering significant long-term revenue growth, gross margin expansion and shareholder value.
Cash, cash equivalents, short-term investments, and restricted cash were approximately $32 million as of June 30, 2025.
For additional details regarding this facility, please refer to the related press release at https://investors.rapidmicrobio.com/news-and-events/news-releases.
Rapid Micro Biosystems will host a conference call on August 12, 2025, at 8:30 a.m. ET to discuss these results, accessible via the company’s website.
Rapid Micro Biosystems provides automation solutions for microbial quality control testing in healthcare product manufacturing. Its Growth Direct system automates testing workflows, delivering faster results and improved efficiency.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com. Media Contact: media@rapidmicrobio.com
Source: Rapid Micro Biosystems
